Xuenong Bo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xuenong Bo has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Dongsheng Wu
School of Engineering and Materials Science, Queen Mary University of London, London, E1 4NS, United Kingdom
5 shared publicationsYi Zhang
Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom
5 shared publicationsJohn Yeh
Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, United Kingdom
4 shared publicationsMin Liu
Affiliation Pain Management and Neuromodulation Centre, Guy’s and St. Thomas’ Hospital, London, United Kingdom
3 shared publicationsSvetlana Gushchina
Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London London UK
3 shared publications- Svetlana Gushchina
Centre for Neuroscience, Surgery and Trauma, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK
3 shared publications
Latest Publications
- Open Access
- 24 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0320463
Effects and predictors of intravenous lidocaine infusion for patients with fibromyalgia
Objective: Fibromyalgia is a chronic pain condition characterised by widespread pain. The current treatment primarily focuses on self-management and symptomatic relief. IV lidocaine infusion is the most performed procedure in the UK that is offered after conventional therapy has failed. We aim to identify the predictors of response to systemic lidocaine to enable targeted treatment for individuals who are more likely to benefit. Methods: This study adheres to the RECORD guidelines for reporting studies using routinely collected observational data. It was conducted retrospectively and employed data derived from clinical records of patients who received standard care. Adult patients who had completed questionnaires and quantitative sensory testing (QST) before IV lidocaine infusion were included. We collected data consecutively from 132 patients, including 24 men and 108 women. Responders were defined as patients who experienced a pain reduction of 50% or greater lasting for at least three weeks following an IV lidocaine infusion at a dose of 5 mg/kg. Results: We identified 22% of patients as responders. Our findings indicate a notable gender disparity in the number of responders, with a response rate of 25.9% observed in female patients compared to 4.2% in male patients (p = 0.02). Functional impairment in the revised fibromyalgia impact questionnaire was higher in female patients than male patients (22.6 ± 5.8 vs 19.8 ± 7.7, p = 0.043). Responders were younger (42.7 ± 11.2 vs 49.4 ± 11.4, p = 0.003), had shorter pain duration in years (10.0 ± 6.1 vs 14.1 ± 9.3, p = 0.015), and lower weekly pain scores (7.8 ± 1.7 vs 8.5 ± 1.4, p = 0.014). No significant difference in QST parameters or loss/gain phenotypes was observed between responders and non-responders. A normal QST was identified in 25% of responders and 16% of non-responders. Consequently, QST alone could not predict the response to systemic lidocaine infusion. Conclusions: IV lidocaine infusion proves effective, especially for younger female patients, which should be added to conventional therapies for these patients.
- 24 July 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (7) , e0320463
Open AccessEffects and predictors of intravenous lidocaine infusion for patients with fibromyalgia
Objective: Fibromyalgia is a chronic pain condition characterised by widespread pain. The current treatment primarily focuses on self-management and symptomatic relief. IV lidocaine infusion is the most performed procedure in the UK that is offered after conventional therapy has failed. We aim to identify the predictors of response to systemic lidocaine to enable targeted treatment for individuals who are more likely to benefit. Methods: This study adheres to the RECORD guidelines for reporting studies using routinely collected observational data. It was conducted retrospectively and employed data derived from clinical records of patients who received standard care. Adult patients who had completed questionnaires and quantitative sensory testing (QST) before IV lidocaine infusion were included. We collected data consecutively from 132 patients, including 24 men and 108 women. Responders were defined as patients who experienced a pain reduction of 50% or greater lasting for at least three weeks following an IV lidocaine infusion at a dose of 5 mg/kg. Results: We identified 22% of patients as responders. Our findings indicate a notable gender disparity in the number of responders, with a response rate of 25.9% observed in female patients compared to 4.2% in male patients (p = 0.02). Functional impairment in the revised fibromyalgia impact questionnaire was higher in female patients than male patients (22.6 ± 5.8 vs 19.8 ± 7.7, p = 0.043). Responders were younger (42.7 ± 11.2 vs 49.4 ± 11.4, p = 0.003), had shorter pain duration in years (10.0 ± 6.1 vs 14.1 ± 9.3, p = 0.015), and lower weekly pain scores (7.8 ± 1.7 vs 8.5 ± 1.4, p = 0.014). No significant difference in QST parameters or loss/gain phenotypes was observed between responders and non-responders. A normal QST was identified in 25% of responders and 16% of non-responders. Consequently, QST alone could not predict the response to systemic lidocaine infusion. Conclusions: IV lidocaine infusion proves effective, especially for younger female patients, which should be added to conventional therapies for these patients.
- Open Access
Effects and predictors of intravenous lidocaine infusion for patients with fibromyalgia
Objective: Fibromyalgia is a chronic pain condition characterised by widespread pain, fatigue, and cognitive function impairment. The current treatment primarily focuses on self-management and symptomatic relief. IV lidocaine infusion is the most performed procedure in the UK that is offered after conventional therapy has failed. We aimed to identify predictors of response to systemic lidocaine to enable targeted treatment for individuals more likely to benefit. Methods: It was a retrospective study at a tertiary pain centre. Adult patients who have completed questionnaires and quantitative sensory testing (QST) before IV lidocaine infusion were included. We collected data from 132 patients, including 24 men and 108 women. Responders were defined as patients who experienced a pain reduction of 50% or greater lasting for at least three weeks following an IV lidocaine infusion at a dose of 5 mg/kg. Results: We identified 22% of patients as responders. Our findings indicate a notable gender disparity in the number of responders, with a response rate of 25.9% observed in female compared to 4.2% in male patients. There was no significant difference in demographic characteristics, pain severity, and sleep interference between male and female patients, except for a higher score in functional impairment among females. Responders were younger, had shorter pain duration, and had lower weekly pain scores. No significant difference in QST parameters or loss/gain phenotypes was observed between responders and non-responders. Conclusions: IV lidocaine infusion proves effective, especially for younger female patients. It should be added to conventional therapies for these patients. More research is needed on gender differences and fibromyalgia subtypes.
Open AccessEffects and predictors of intravenous lidocaine infusion for patients with fibromyalgia
Objective: Fibromyalgia is a chronic pain condition characterised by widespread pain, fatigue, and cognitive function impairment. The current treatment primarily focuses on self-management and symptomatic relief. IV lidocaine infusion is the most performed procedure in the UK that is offered after conventional therapy has failed. We aimed to identify predictors of response to systemic lidocaine to enable targeted treatment for individuals more likely to benefit. Methods: It was a retrospective study at a tertiary pain centre. Adult patients who have completed questionnaires and quantitative sensory testing (QST) before IV lidocaine infusion were included. We collected data from 132 patients, including 24 men and 108 women. Responders were defined as patients who experienced a pain reduction of 50% or greater lasting for at least three weeks following an IV lidocaine infusion at a dose of 5 mg/kg. Results: We identified 22% of patients as responders. Our findings indicate a notable gender disparity in the number of responders, with a response rate of 25.9% observed in female compared to 4.2% in male patients. There was no significant difference in demographic characteristics, pain severity, and sleep interference between male and female patients, except for a higher score in functional impairment among females. Responders were younger, had shorter pain duration, and had lower weekly pain scores. No significant difference in QST parameters or loss/gain phenotypes was observed between responders and non-responders. Conclusions: IV lidocaine infusion proves effective, especially for younger female patients. It should be added to conventional therapies for these patients. More research is needed on gender differences and fibromyalgia subtypes.
- Open Access
- 13 January 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (1) , e1229
Gender differences in clinical presentations and sensory profiles in patients with fibromyalgia: implications of peripheral and central mechanisms
Introduction: Fibromyalgia has a high female predominance and research work has been focussing mainly on women. Objectives: We aimed to answer (1) gender differences in pain scores and quality of life, (2) any gender-specific subgroups defined by quantitative sensory testing (QST), and (3) correlations of QST parameters with pain intensity and questionnaire scores. Methods: We evaluated clinical presentations and QST profiles from 38 male and 38 age-matched female patients. Results: Women reported significantly higher scores in average daily pain, daily sleep interference score, average weekly pain, weekly sleep interference score, and revised fibromyalgia impact questionnaire (rFIQ). Based on LOGA classification, L0G2, mechanical allodynia or hyperalgesia without abnormal sensory loss, was the most common QST subtype which accounted for 28.9% of men and 26.3% of women. Approximately 34.2% of men and 26.3% of women displayed loss of function of small fibres with an increased cold or warm detection threshold. Cold detection threshold was negatively correlated with pain intensity and functional impairment, suggesting a peripheral mechanism. Central sensitization, defined as allodynia and hyperalgesia to thermal or mechanical stimuli, was found in two-thirds of male and female patients. Mechanical pain sensitivity was positively correlated with the severity of pain and associated symptoms in women, but not men. Conclusion: There was a marked gender difference in reported pain and quality of life. We have confirmed that central sensitization is a major mechanism for women. Our data suggested an important role of small fibre pathology in both men and women.
- 13 January 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (1) , e1229
Open AccessGender differences in clinical presentations and sensory profiles in patients with fibromyalgia: implications of peripheral and central mechanisms
Introduction: Fibromyalgia has a high female predominance and research work has been focussing mainly on women. Objectives: We aimed to answer (1) gender differences in pain scores and quality of life, (2) any gender-specific subgroups defined by quantitative sensory testing (QST), and (3) correlations of QST parameters with pain intensity and questionnaire scores. Methods: We evaluated clinical presentations and QST profiles from 38 male and 38 age-matched female patients. Results: Women reported significantly higher scores in average daily pain, daily sleep interference score, average weekly pain, weekly sleep interference score, and revised fibromyalgia impact questionnaire (rFIQ). Based on LOGA classification, L0G2, mechanical allodynia or hyperalgesia without abnormal sensory loss, was the most common QST subtype which accounted for 28.9% of men and 26.3% of women. Approximately 34.2% of men and 26.3% of women displayed loss of function of small fibres with an increased cold or warm detection threshold. Cold detection threshold was negatively correlated with pain intensity and functional impairment, suggesting a peripheral mechanism. Central sensitization, defined as allodynia and hyperalgesia to thermal or mechanical stimuli, was found in two-thirds of male and female patients. Mechanical pain sensitivity was positively correlated with the severity of pain and associated symptoms in women, but not men. Conclusion: There was a marked gender difference in reported pain and quality of life. We have confirmed that central sensitization is a major mechanism for women. Our data suggested an important role of small fibre pathology in both men and women.
- Open Access
Combination of Engineered Expression of Polysialic Acid on Transplanted Schwann Cells and in Injured Rat Spinal Cord Promotes Significant Axonal Growth and Functional Recovery
Providing cellular support and modifying the glial scar around the lesion are two key strategies for promoting axonal regeneration after spinal cord injury. We showed previously that over-expressing polysialic acid (PSA) on Schwann cells (SCs) by lentiviral vector (LV)-mediated expression of polysialyltransferase (PST) facilitated their integration and migration in the injured spinal cord. We also showed that PSA over-expression in the injured spinal cord modified the glial scar and promoted the growth of ascending sensory axons. In this study, we combined the PST/SC transplantation with LV/PST injection in spinal cords after dorsal column transection and found the combined treatments led to faster and more profound locomotor functional recovery compared with animals receiving combined GFP/SC transplantation with LV/GFP injection. Histological examination showed significantly more injured corticospinal axons growing close to the lesion/transplant borders and into the caudal spinal cord in the PST group than in the GFP group. We also found over -expressing PSA around the lesion site did not cause allodynia and hyperalgesia in our injury model. These results demonstrate the promising therapeutic benefit of over-expressing PSA in transplanted SCs and spinal cord in promoting axonal growth and restoring motor function.
Open AccessCombination of Engineered Expression of Polysialic Acid on Transplanted Schwann Cells and in Injured Rat Spinal Cord Promotes Significant Axonal Growth and Functional Recovery
Providing cellular support and modifying the glial scar around the lesion are two key strategies for promoting axonal regeneration after spinal cord injury. We showed previously that over-expressing polysialic acid (PSA) on Schwann cells (SCs) by lentiviral vector (LV)-mediated expression of polysialyltransferase (PST) facilitated their integration and migration in the injured spinal cord. We also showed that PSA over-expression in the injured spinal cord modified the glial scar and promoted the growth of ascending sensory axons. In this study, we combined the PST/SC transplantation with LV/PST injection in spinal cords after dorsal column transection and found the combined treatments led to faster and more profound locomotor functional recovery compared with animals receiving combined GFP/SC transplantation with LV/GFP injection. Histological examination showed significantly more injured corticospinal axons growing close to the lesion/transplant borders and into the caudal spinal cord in the PST group than in the GFP group. We also found over -expressing PSA around the lesion site did not cause allodynia and hyperalgesia in our injury model. These results demonstrate the promising therapeutic benefit of over-expressing PSA in transplanted SCs and spinal cord in promoting axonal growth and restoring motor function.
- Open Access
- 9 August 2023
- Published by MDPI AG in Preprints.org
Combination of Engineered Expression of Polysialic Acid on Transplanted Schwann Cells and in Injured Rat Spinal Cord Promotes Significant Axonal Growth and Functional Recovery
Providing cellular support and modifying the glial scar around the lesion are two key strategies for promoting axonal regeneration after spinal cord injury. We showed before that over-expressing polysialic acid (PSA) on Schwann cells (SCs) by lentiviral vector (LV)-mediated expression of polysialyltransferase (PST) facilitated their integration and migration in the injured spinal cord. We also showed that PSA over-expression in the injured spinal cord modified the glial scar and promoted the growth of ascending sensory axons. In this study, we combined the PST/SC transplantation with LV/PST injection in spinal cords after dorsal column transection and found the combined treatments led to faster and more profound locomotor functional recovery compared with animals receiving combined GFP/SC transplantation with LV/GFP injection. Histological examination showed significantly more injured corticospinal axons growing close to the lesion/transplant borders and into the caudal spinal cord in the PST group than in the GFP group. We also found over-expressing PSA around the lesion site did not cause allodynia and hyperalgesia in our injury model. These results demonstrate the promising therapeutic benefit of over-expressing PSA in transplanted SCs and spinal cord in promoting axonal growth and restoring motor function.
- 9 August 2023
- Published by MDPI AG in Preprints.org
Open AccessCombination of Engineered Expression of Polysialic Acid on Transplanted Schwann Cells and in Injured Rat Spinal Cord Promotes Significant Axonal Growth and Functional Recovery
Providing cellular support and modifying the glial scar around the lesion are two key strategies for promoting axonal regeneration after spinal cord injury. We showed before that over-expressing polysialic acid (PSA) on Schwann cells (SCs) by lentiviral vector (LV)-mediated expression of polysialyltransferase (PST) facilitated their integration and migration in the injured spinal cord. We also showed that PSA over-expression in the injured spinal cord modified the glial scar and promoted the growth of ascending sensory axons. In this study, we combined the PST/SC transplantation with LV/PST injection in spinal cords after dorsal column transection and found the combined treatments led to faster and more profound locomotor functional recovery compared with animals receiving combined GFP/SC transplantation with LV/GFP injection. Histological examination showed significantly more injured corticospinal axons growing close to the lesion/transplant borders and into the caudal spinal cord in the PST group than in the GFP group. We also found over-expressing PSA around the lesion site did not cause allodynia and hyperalgesia in our injury model. These results demonstrate the promising therapeutic benefit of over-expressing PSA in transplanted SCs and spinal cord in promoting axonal growth and restoring motor function.
- Open Access
- 1 January 2022
- Published by Medknow in Neural Regeneration Research
- Vol. 17 (4) , 773-774
Colony stimulating factor 1: friend or foe of neurons?
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
- 1 January 2022
- Published by Medknow in Neural Regeneration Research
- Vol. 17 (4) , 773-774
Open AccessColony stimulating factor 1: friend or foe of neurons?
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
Alleviation of neuropathic pain by over‐expressing a soluble colony‐stimulating factor 1 receptor to suppress microgliosis and macrophage accumulation
Microglial proliferation and activation and macrophage accumulation are implicated in neuropathic pain development. In this study, we aim to suppress microgliosis and macrophage accumulation by over‐expressing a non‐functional soluble colony stimulating factor‐1 receptor (sCSF1R) using an adeno‐associated virus 9 vector (AAV9). AAV9/sCSF1R and the control vector AAV9/GFP were intrathecally administered into the lumbar spine of adult C57BL/6 mice. Two weeks later, these mice underwent partial sciatic nerve ligation to induce neuropathic pain. GFP and sCSF1R were highly expressed in lumbar dorsal root ganglia (DRG) and spinal cord of AAV9‐injected mice. A significant increase in microglia densities in the dorsal and ventral horns of lumbar spinal cords and macrophage densities in DRG and sciatic nerves were observed in the mice with either ligation alone or pre‐treated with AAV9/GFP. In nerve‐ligated mice pre‐treated with AAV9/sCSF1R the microglia densities in the dorsal and ventral horns and macrophage densities in DRG and sciatic nerves were significantly lower compared to nerve‐ligated mice pre‐treated with AAV9/GFP. Behavioral tests showed that nerve‐ligated mice pre‐treated with AAV9/sCSF1R had a significantly higher paw withdrawal threshold, indicating the alleviation of neuropathic pain. The results implicate that viral vector‐mediated expression of sCSF1R may represent a novel strategy in the alleviation of neuropathic pain.
Alleviation of neuropathic pain by over‐expressing a soluble colony‐stimulating factor 1 receptor to suppress microgliosis and macrophage accumulation
Microglial proliferation and activation and macrophage accumulation are implicated in neuropathic pain development. In this study, we aim to suppress microgliosis and macrophage accumulation by over‐expressing a non‐functional soluble colony stimulating factor‐1 receptor (sCSF1R) using an adeno‐associated virus 9 vector (AAV9). AAV9/sCSF1R and the control vector AAV9/GFP were intrathecally administered into the lumbar spine of adult C57BL/6 mice. Two weeks later, these mice underwent partial sciatic nerve ligation to induce neuropathic pain. GFP and sCSF1R were highly expressed in lumbar dorsal root ganglia (DRG) and spinal cord of AAV9‐injected mice. A significant increase in microglia densities in the dorsal and ventral horns of lumbar spinal cords and macrophage densities in DRG and sciatic nerves were observed in the mice with either ligation alone or pre‐treated with AAV9/GFP. In nerve‐ligated mice pre‐treated with AAV9/sCSF1R the microglia densities in the dorsal and ventral horns and macrophage densities in DRG and sciatic nerves were significantly lower compared to nerve‐ligated mice pre‐treated with AAV9/GFP. Behavioral tests showed that nerve‐ligated mice pre‐treated with AAV9/sCSF1R had a significantly higher paw withdrawal threshold, indicating the alleviation of neuropathic pain. The results implicate that viral vector‐mediated expression of sCSF1R may represent a novel strategy in the alleviation of neuropathic pain.
- Open Access
Alleviation of neuropathic pain by over-expressing a soluble colony-stimulating factor 1 receptor
In this study, we aim to alleviate neuropathic pain by suppressing microgliosis and macrophage accumulation, which is achieved by over-expressing a non-functional soluble colony-stimulating factor 1 receptor using adeno-associated virus 9 vectors (AAV9/sCSF1R). AAV9/sCSF1R and AAV9/GFP were intrathecally administered into mouse lumbar spine. Two weeks later, these mice underwent partial sciatic nerve ligation to induce neuropathic pain. GFP and sCSF1R were highly expressed in dorsal root ganglia (DRG) and spinal cords in AAV9-injected mice. Nerve ligation alone or pre-treated with AAV9/GFP led to significant microgliosis in the lumbar spinal cords and macrophage accumulation in DRG and sciatic nerves. In nerve-ligated mice pre- treated with AAV9/sCSF1R the microglia densities in the dorsal and ventral horns and macrophage densities in DRG and sciatic nerves were significantly lower compared to nerve-ligated mice pre-treated with AAV9/GFP. Behavioural tests showed that nerve-ligated mice pre- treated with AAV9/sCSF1R had a significantly higher paw withdrawal threshold, indicating the alleviation of neuropathic pain. The results implicate that viral vector-mediated expression of sCSF1R may represent a novel strategy in long-term alleviation of neuropathic pain.
Open AccessAlleviation of neuropathic pain by over-expressing a soluble colony-stimulating factor 1 receptor
In this study, we aim to alleviate neuropathic pain by suppressing microgliosis and macrophage accumulation, which is achieved by over-expressing a non-functional soluble colony-stimulating factor 1 receptor using adeno-associated virus 9 vectors (AAV9/sCSF1R). AAV9/sCSF1R and AAV9/GFP were intrathecally administered into mouse lumbar spine. Two weeks later, these mice underwent partial sciatic nerve ligation to induce neuropathic pain. GFP and sCSF1R were highly expressed in dorsal root ganglia (DRG) and spinal cords in AAV9-injected mice. Nerve ligation alone or pre-treated with AAV9/GFP led to significant microgliosis in the lumbar spinal cords and macrophage accumulation in DRG and sciatic nerves. In nerve-ligated mice pre- treated with AAV9/sCSF1R the microglia densities in the dorsal and ventral horns and macrophage densities in DRG and sciatic nerves were significantly lower compared to nerve-ligated mice pre-treated with AAV9/GFP. Behavioural tests showed that nerve-ligated mice pre- treated with AAV9/sCSF1R had a significantly higher paw withdrawal threshold, indicating the alleviation of neuropathic pain. The results implicate that viral vector-mediated expression of sCSF1R may represent a novel strategy in long-term alleviation of neuropathic pain.
- Open Access
- 1 December 2018
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 13 (12) , 2077-2079
Is ATP a key player in conditioning neurons to support axonal regeneration?
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
- 1 December 2018
- Published by Wolters Kluwer Health in Neural Regeneration Research
- Vol. 13 (12) , 2077-2079
Open AccessIs ATP a key player in conditioning neurons to support axonal regeneration?
Neural Regen Res, Official publication of Publishing House of Neural Regeneration Research China Association of Rehabilitation Medicine,China
Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss
Microglia contribute to pathophysiology at all stages of multiple sclerosis. Colony‐stimulating factor‐1 (CSF1) is crucial for microglial proliferation and activation. In this study we measured the CSF1 levels and studied its cellular expression in the mouse spinal cords with experimental autoimmune encephalomyelitis (EAE) to explore the potential contribution of CSF1 in neuronal death. ELISA data showed that CSF1 levels were significantly higher in the spinal cords with acute and chronic EAE than those of normal and adjuvant‐injected mice. Immunohistochemical studies demonstrated that CSF1 was expressed in astrocytes and neurons in normal mouse spinal cord. In acute EAE, CSF1 expression was significantly increased, especially in astrocytes in peripheral white matter and large motoneurons. High density of activated microglia was observed in the gray matter where motoneurons expressed high‐level CSF1 in acute EAE. Significant large motoneuron loss was seen in chronic EAE and the remaining motoneurons with high‐level CSF1 were enwrapped by microglia. Viral vector mediated over‐expression of CSF1 in spinal neurons induced profound proliferation and activation of microglia at the injection site and microglia enwrapped CSF1‐transduced neurons and their neurites. Significant loss of large CSF1‐transduced neurons was seen at 2 and 3 weeks post‐viral injection. Demyelination in the CSF1‐transduced areas was also significant. These results implicate that CSF1 upregulation in CNS may play an important role in the proliferation and activation of microglia in EAE, contributing to neuroinflammation and neurodegeneration.
Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss
Microglia contribute to pathophysiology at all stages of multiple sclerosis. Colony‐stimulating factor‐1 (CSF1) is crucial for microglial proliferation and activation. In this study we measured the CSF1 levels and studied its cellular expression in the mouse spinal cords with experimental autoimmune encephalomyelitis (EAE) to explore the potential contribution of CSF1 in neuronal death. ELISA data showed that CSF1 levels were significantly higher in the spinal cords with acute and chronic EAE than those of normal and adjuvant‐injected mice. Immunohistochemical studies demonstrated that CSF1 was expressed in astrocytes and neurons in normal mouse spinal cord. In acute EAE, CSF1 expression was significantly increased, especially in astrocytes in peripheral white matter and large motoneurons. High density of activated microglia was observed in the gray matter where motoneurons expressed high‐level CSF1 in acute EAE. Significant large motoneuron loss was seen in chronic EAE and the remaining motoneurons with high‐level CSF1 were enwrapped by microglia. Viral vector mediated over‐expression of CSF1 in spinal neurons induced profound proliferation and activation of microglia at the injection site and microglia enwrapped CSF1‐transduced neurons and their neurites. Significant loss of large CSF1‐transduced neurons was seen at 2 and 3 weeks post‐viral injection. Demyelination in the CSF1‐transduced areas was also significant. These results implicate that CSF1 upregulation in CNS may play an important role in the proliferation and activation of microglia in EAE, contributing to neuroinflammation and neurodegeneration.